PMID- 19228604
OWN - NLM
STAT- MEDLINE
DCOM- 20090305
LR  - 20240312
IS  - 1524-4636 (Electronic)
IS  - 1079-5642 (Print)
IS  - 1079-5642 (Linking)
VI  - 29
IP  - 3
DP  - 2009 Mar
TI  - New insights into cancer-associated thrombosis.
PG  - 316-20
LID - 10.1161/ATVBAHA.108.182196 [doi]
AB  - Venous thromboembolism (VTE) is an increasingly frequent complication of 
      anticancer therapy. The underlying mechanisms are not completely understood, but 
      are related in part to oncogene activation and tissue factor (TF) expression. 
      Several risk factors have been identified including site and stage of cancer, 
      patient comorbidities, and specific therapeutic agents. Candidate biomarkers such 
      as blood counts, TF, and P-selectin have recently been identified. A risk model 
      predictive of chemotherapy-associated VTE has been validated. Thromboprophylaxis 
      with low molecular weight heparin (LMWH), unfractionated heparin (UFH), or 
      fondaparinux is recommended for hospitalized medical and surgical cancer 
      patients. Long-term anticoagulation with LMWH is safe and effective in reducing 
      recurrent VTE in cancer. The role of thromboprophylaxis in ambulatory cancer 
      patients receiving chemotherapy is an area of active investigation.
FAU - Sousou, Tarek
AU  - Sousou T
AD  - James P. Wilmot Cancer Center and the Department of Medicine, University of 
      Rochester, NY, USA.
FAU - Khorana, Alok A
AU  - Khorana AA
LA  - eng
GR  - K23 CA120587/CA/NCI NIH HHS/United States
GR  - K23 CA120587-03/CA/NCI NIH HHS/United States
GR  - R01 HL095109/HL/NHLBI NIH HHS/United States
GR  - 1R01HL095109-01/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Arterioscler Thromb Vasc Biol
JT  - Arteriosclerosis, thrombosis, and vascular biology
JID - 9505803
RN  - 0 (Anticoagulants)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Antineoplastic Agents/*adverse effects
MH  - Biomarkers/blood
MH  - Blood Coagulation/*drug effects
MH  - Humans
MH  - Neoplasms/blood/*complications/drug therapy
MH  - Predictive Value of Tests
MH  - Risk Assessment
MH  - Risk Factors
MH  - Secondary Prevention
MH  - Treatment Outcome
MH  - Venous Thromboembolism/blood/drug therapy/*etiology/prevention & control
PMC - PMC2727713
MID - NIHMS126042
EDAT- 2009/02/21 09:00
MHDA- 2009/03/06 09:00
PMCR- 2010/03/01
CRDT- 2009/02/21 09:00
PHST- 2009/02/21 09:00 [entrez]
PHST- 2009/02/21 09:00 [pubmed]
PHST- 2009/03/06 09:00 [medline]
PHST- 2010/03/01 00:00 [pmc-release]
AID - 29/3/316 [pii]
AID - 10.1161/ATVBAHA.108.182196 [doi]
PST - ppublish
SO  - Arterioscler Thromb Vasc Biol. 2009 Mar;29(3):316-20. doi: 
      10.1161/ATVBAHA.108.182196.